Apremilast (3) – Otezla®
Moderate to severe plaque psoriasis; 6 to < 18 years of age
Characteristics
| Start date | 15.11.2024 – Marketing authorisation: 21.10.2024 |
|---|---|
| Resolution | 15.05.2025 |
| INN | Apremilast |
| Brand name | Otezla® |
| Pharm. company | Amgen GmbH |
| G-BA Procedure ID | D-1124 |
| ATC code | L04AA32 Selective immunosuppressants (L04AA) |
| ICD-10 codes (AIS) | L40.0Nummular psoriasis |
| Alpha-ID codes (AIS) | I109655Plaque psoriasis |
| Therapeutic area | Skin diseases Plaque psoriasis (PP) |
| Reason for procedure | New therapeutic indication |
| Specialty | Patent/data protection expired |
| Therapeutic indication of the resolution |
|---|
|
Otezla is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents aged 6 to < 18 years and with a body weight of at least 20 kg for whom systemic therapy is an option. |
| Subpopulation | Indication | Comparator |
|---|---|---|
| Children and adolescents aged 6 to < 18 years and with a body weight of at least 20 kg with moderate to severe plaque psoriasis for whom systemic therapy is an option | Adalimumab or etanercept or secukinumab or ustekinumab |
Studies and Results
|
No. of studies
(best subpopulation) |
0 (Data not accepted) |
|---|---|
|
Study design
(best subpopulation) |
Data not accepted (Dossier: no data submitted) |
- Clinical trials
- The pharmaceutical manufacturer has submitted the SPROUT trial, on which the marketing authorisation is based, in which apremilast was compared with placebo in children and adolescents over a period of 16 weeks.
Children and adolescents aged 6 to < 18 years and weighing at least 20 kg with moderate to severe plaque psoriasis for whom systemic therapy is an option
- For children and adolescents aged 6 to < 18 years and weighing at least 20 kg with moderate to severe plaque psoriasis for whom systemic therapy is an option, the additional benefit compared with the appropriate comparator therapy is not proven.
- The pharmaceutical manufacturer has not identified any comparative studies against the appropriate comparator therapy for the assessment of the additional benefit of apremilast.
- Due to the lack of comparison with the appropriate comparator therapy, the study is not suitable for assessing additional benefit.
- On balance, the G-BA therefore concludes that for children and adolescents aged 6 to < 18 years and weighing at least 20 kg with moderate to severe plaque psoriasis for whom systemic therapy is an option, The additional benefit of apremilast compared with the appropriate comparator therapy is not proven.
- Overall assessment
- On balance, the G-BA therefore concludes that for children and adolescents aged 6 to < 18 years and weighing at least 20 kg with moderate to severe plaque psoriasis, for whom systemic therapy is an option, The additional benefit of apremilast compared with the appropriate comparator therapy is not proven.
Courtesy translation only, please refer to the German original.
Associated procedures
| Apremilast (3) | Otezla® | Amgen GmbH | Moderate to severe plaque psoriasis; 6 to < 18 years of age | 360–430 | 100% additional benefit not proven | |
| Apremilast (2) | Otezla® | Amgen GmbH | Behçet's disease | 750–2,200 | 100% additional benefit not proven | |
| Apremilast (1) | Otezla® | Celgene GmbH | Plaque psoriasis (PP); Psoriatic arthritis (PA) | 50,800–140,500 | 100% additional benefit not proven |
<< List of all resolutions